HSBC downgrades Illumina on China risks, funding concerns
HSBC noted that Illumina is losing its market dominance, with declining instrument placements in the low-to-mid throughput ...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or ...
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...